Register Early and Save!

Register by June 22 and Save $500 off the standard rates

Call for Posters

Deadline: September 7
» Submit your proposal

Keynote Presentations

The Next Generation of Biotherapeutic Dosage Forms

Kevin R. King, Ph.D.,
Senior Director, Formulation & Process Development, Pfizer Inc.

Experiences in a QbD-Based FDA Regulatory Filing: Drug Product Considerations

Mary E.M. Cromwell, Ph.D.,
Director, Late Stage Pharmaceutical Development, Genentech, Inc.

The Next Generation of Biologics and the Role of Drug Delivery and Device Technologies

William J. Lambert, Ph.D.,
Fellow, Drug Delivery and Device Development, MedImmune, Inc.

Special Discounted Hotel Rate

Special Discounted Hotel Rate Available Until September 7, 2012.
To book your room, call 1-888-627-8449 and mention that you are an IBC attendee at this event.

Co-located with:

Experience the networking opportunities of IBC's co-located BioProcess International Conference & Exhibition.

Extended Programming:
IBC's 12th Annual
Formulation Strategies for Protein Therapeutics
October 9-10, 2012
Providence, RI

Delivery Strategies blends practical solutions related to the development of high dose drug products and drug/device combinations with forward looking information on novel delivery approaches for biotherapeutics.

Developing the Next Generation of Biotherapeutics

Conference Sessions Explore the Emerging Science Behind Targeted Biologics Delivery and Next-Generation Routes of Administration:

• Delivery Strategies for High Viscosity and High Concentration Drug Products
• Co-Development Strategies for Biologic-Device Product Combinations
• Localized and Targeted Delivery of Biologics
• Next Generation Routes of Administration for Biologics

Explore Best Practices in the Development of Delivery Methods:

The Formulation and Delivery conferences feature 25 Case Studies from these leading companies and much more:

• Abbott
• Amgen
• Biocon Limited, India
• Bristol-Myers Squibb
• Genzyme Corporation, a Sanofi company
• Human Genome Sciences
• MedImmune, Inc.
• Novartis Pharma AG, Switzerland
• Pfizer, Inc.
• Regeneron Pharmaceuticals Inc.
• Shire
• Zyngenia

Presentation Highlights:

• Medimmune describes the roles drug delivery and device technologies will play in the development of second-generation biologics and biosimilars.
• Amgen offers a set of practical strategies for the excipient-based formulation of high concentration protein products.
• Novartis presents a strategy for drugdevice development focusing on the early selection of devices and their functionality for therapeutic delivery.
• The University of Michigan details microencapsulation approaches for controlled-release depots for biomacromolecules that minimize protein damage, organic-solvent use, and costly aseptic manufacturing.
• Brown University and Entrega explore innovative strategies for the oral delivery of protein therapeutics.